Literature DB >> 7880727

The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.

P Nygren1, K Csoka, B Jonsson, H Fridborg, J Bergh, H Hagberg, B Glimelius, O Brodin, B Tholander, A Kreuger.   

Abstract

In patient tumour samples the activity in vitro of Taxol corresponded fairly well to the known clinical activity and Taxol showed low cross-resistance to standard cytotoxic drugs. However, the Taxol solvent Cremophor EL--ethanol was considerably active alone, whereas paclitaxel formulated in ethanol was less active. Taxol thus seems to contain two components active against patient tumour cells in vitro.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7880727      PMCID： PMC2033622          DOI： 10.1038/bjc.1995.97

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  19 in total

1.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Authors:  F A Holmes; R S Walters; R L Theriault; A D Forman; L K Newton; M N Raber; A U Buzdar; D K Frye; G N Hortobagyi
Journal:  J Natl Cancer Inst       Date:  1991-12-18       Impact factor: 13.506

2.  Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients.

Authors:  P Nygren; H Fridborg; K Csoka; C Sundström; M de la Torre; J Kristensen; J Bergh; H Hagberg; B Glimelius; J Rastad
Journal:  Int J Cancer       Date:  1994-03-01       Impact factor: 7.396

3.  Phase II trial of taxol in patients with metastatic renal cell carcinoma.

Authors:  A I Einzig; E Gorowski; J Sasloff; P H Wiernik
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

4.  Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

Authors:  L Webster; M Linsenmeyer; M Millward; C Morton; J Bishop; D Woodcock
Journal:  J Natl Cancer Inst       Date:  1993-10-20       Impact factor: 13.506

5.  Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

Authors:  A I Einzig; P H Wiernik; J Sasloff; C D Runowicz; G L Goldberg
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

6.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

Authors:  W K Murphy; F V Fossella; R J Winn; D M Shin; H E Hynes; H M Gross; E Davilla; J Leimert; H Dhingra; M N Raber
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

7.  In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.

Authors:  J Kristensen; B Jonsson; C Sundström; P Nygren; R Larsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

8.  Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia.

Authors:  P Nygren; J Kristensen; B Jonsson; C Sundström; G Lönnerholm; A Kreuger; R Larsson
Journal:  Leukemia       Date:  1992-11       Impact factor: 11.528

9.  SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.

Authors:  B Jonsson; K Nilsson; P Nygren; R Larsson
Journal:  Anticancer Drugs       Date:  1992-12       Impact factor: 2.248

Review 10.  Taxol: the first of the taxanes, an important new class of antitumor agents.

Authors:  E K Rowinsky; N Onetto; R M Canetta; S G Arbuck
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929
View more
  11 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.

Authors:  T A Dunn; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Authors:  Ake Berglund; Bengt Glimelius; Jonas Bergh; Ola Brodin; Marie-Louise Fjällskog; Hans Hagberg; Anne von Heideman; Rolf Larsson; Bengt Tholander; Manuel de la Torre; Gunnar Aström; Kjell Oberg; Gunnar Parö; Peter Nygren
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

4.  Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro.

Authors:  L Plasswilm; N Cordes; R Fietkau; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

5.  Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells.

Authors:  N Cordes; L Plasswilm; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-04       Impact factor: 3.621

Review 6.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.

Authors:  A J Terzis; F Thorsen; O Heese; T Visted; R Bjerkvig; O Dahl; H Arnold; G Gundersen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

Authors:  E Jonsson; H Fridborg; K Csóka; S Dhar; C Sundström; P Nygren; R Larsson
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Authors:  S Dhar; P Nygren; K Csoka; J Botling; K Nilsson; R Larsson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  R Larsson; S Dhar; H Ehrsson; P Nygren; R Lewensohn
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.